The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung ...

The drug, marketed under the name Imdelltra, is part of Amgen's pipeline of bispecific antibodies designed to attach to a ...

The treatment is for patients with small cell lung cancer, which afflicts about 35,000 people in the U.S. a year.

Immunotherapy can boost the survival of early-stage lung cancer patients eligible for surgery when it's combined with ...

Those who got immunotherapy before and after surgery -- along with pre-surgical chemo -- had a 42% lower risk of cancer ...

Continued approval of the first-in-class bispecific T-cell engager (BiTE) may depend on proof of clinical benefit.

The FDA cleared the Amgen drug, called Imdelltra, as a treatment for patients with advanced small-cell lung cancer.

Many are unaware that they qualify, or have misconceptions about what to expect. Stigmas about smoking also are a barrier.

Seven months after Amgen’s chief medical officer referred to trial results for the company's investigational lung cancer ...

The FDA approved an innovative treatment from Amgen for patients with small cell lung cancer who have exhausted all other ...

Lung cancer remains a leading global health concern, responsible for the highest number of cancer-related deaths worldwide.